

Antonio J Vallejo-Vaz

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1415159/publications.pdf>

Version: 2024-02-01

50
papers

2,245
citations

304743

22
h-index

223800

46
g-index

54
all docs

54
docs citations

54
times ranked

3076
citing authors

#	ARTICLE	IF	CITATIONS
1	Prevalence of Familial Hypercholesterolemia Among the General Population and Patients With Atherosclerotic Cardiovascular Disease. <i>Circulation</i> , 2020, 141, 1742-1759.	1.6	301
2	Olive Oil Polyphenols Decrease Blood Pressure and Improve Endothelial Function in Young Women with Mild Hypertension. <i>American Journal of Hypertension</i> , 2012, 25, 1299-304.	2.0	169
3	Reducing the Clinical and Public Health Burden of Familial Hypercholesterolemia. <i>JAMA Cardiology</i> , 2020, 5, 217.	6.1	169
4	Overview of the current status of familial hypercholesterolaemia care in over 60 countries - The EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC). <i>Atherosclerosis</i> , 2018, 277, 234-255.	0.8	163
5	Familial hypercholesterolaemia: A global call to arms. <i>Atherosclerosis</i> , 2015, 243, 257-259.	0.8	148
6	Low-Density Lipoprotein Cholesterol Lowering for the Primary Prevention of Cardiovascular Disease Among Men With Primary Elevations of Low-Density Lipoprotein Cholesterol Levels of 190 mg/dL or Above. <i>Circulation</i> , 2017, 136, 1878-1891.	1.6	144
7	Global perspective of familial hypercholesterolaemia: a cross-sectional study from the EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC). <i>Lancet, The</i> , 2021, 398, 1713-1725.	13.7	142
8	Triglyceride-Rich Lipoprotein Cholesterol and Risk of Cardiovascular Events Among Patients Receiving Statin Therapy in the TNT Trial. <i>Circulation</i> , 2018, 138, 770-781.	1.6	126
9	Pooling and expanding registries of familial hypercholesterolaemia to assess gaps in care and improve disease management and outcomes: Rationale and design of the global EAS Familial Hypercholesterolaemia Studies Collaboration. <i>Atherosclerosis Supplements</i> , 2016, 22, 1-32.	1.2	90
10	Effect of pitavastatin on glucose, HbA1c and incident diabetes: A meta-analysis of randomized controlled clinical trials in individuals without diabetes. <i>Atherosclerosis</i> , 2015, 241, 409-418.	0.8	87
11	Worldwide experience of homozygous familial hypercholesterolaemia: retrospective cohort study. <i>Lancet, The</i> , 2022, 399, 719-728.	13.7	69
12	Lipoprotein(a) reductions from PCSK9 inhibition and major adverse cardiovascular events: Pooled analysis of alirocumab phase 3 trials. <i>Atherosclerosis</i> , 2019, 288, 194-202.	0.8	56
13	Triglycerides and residual risk. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 2020, 27, 95-103.	2.3	42
14	Role of the Renin-Angiotensin System and Aldosterone on Cardiometabolic Syndrome. <i>International Journal of Hypertension</i> , 2011, 2011, 1-8.	1.3	39
15	Epidemiology of familial hypercholesterolaemia: Community and clinical. <i>Atherosclerosis</i> , 2018, 277, 289-297.	0.8	39
16	Role of Circulating Cell-free DNA Levels in Patients With Severe Preeclampsia and HELLP Syndrome. <i>American Journal of Hypertension</i> , 2013, 26, 1377-1380.	2.0	36
17	Impact of statin therapy on plasma levels of plasminogen activator inhibitor-1. <i>Thrombosis and Haemostasis</i> , 2016, 116, 162-171.	3.4	32
18	Obstructive Sleep Apnea Syndrome, Vascular Pathology, Endothelial Function and Endothelial Cells and Circulating Microparticles. <i>Archives of Medical Research</i> , 2013, 44, 409-414.	3.3	31

#	ARTICLE	IF	CITATIONS
19	Obstructive Sleep Apnoea Syndrome, Endothelial Function and Markers of Endothelialization. Changes after CPAP. PLoS ONE, 2015, 10, e0122091.	2.5	31
20	Total and Fetal Circulating Cell-Free DNA, Angiogenic, and Antiangiogenic Factors in Preeclampsia and HELLP Syndrome. American Journal of Hypertension, 2017, 30, 673-682.	2.0	28
21	Which parameter is better to define endothelial dysfunction in a test of postocclusive hyperemia measured by Laser-Doppler flowmetry?. Coronary Artery Disease, 2012, 23, 57-61.	0.7	26
22	Relation of Fasting Triglyceride-Rich Lipoprotein Cholesterol to Coronary Artery Calcium Score (from the ELSA-Brasil Study). American Journal of Cardiology, 2017, 119, 1352-1358.	1.6	26
23	Non-HDL cholesterol goal attainment and its relationship with triglyceride concentrations among diabetic subjects with cardiovascular disease: A nationwide survey of 2674 individuals in Hungary. Atherosclerosis, 2015, 241, 62-68.	0.8	18
24	A meta-analysis of medications directed against PCSK9 in familial hypercholesterolemia. Atherosclerosis, 2021, 325, 46-56.	0.8	18
25	Effect of computerised, knowledge-based, clinical decision support systems on patient-reported and clinical outcomes of patients with chronic disease managed in primary care settings: a systematic review. BMJ Open, 2021, 11, e054659.	1.9	18
26	Fibrate therapy and flow-mediated dilation: A systematic review and meta-analysis of randomized placebo-controlled trials. Pharmacological Research, 2016, 111, 163-179.	7.1	17
27	Maternal Body-Mass Index and Cord Blood Circulating Endothelial Colony-Forming Cells. Journal of Pediatrics, 2014, 164, 566-571.	1.8	16
28	Associations between lower levels of low-density lipoprotein cholesterol and cardiovascular events in very high-risk patients: Pooled analysis of nine ODYSSEY trials of alirocumab versus control. Atherosclerosis, 2019, 288, 85-93.	0.8	16
29	Isolated abducens nerve palsy in preeclampsia and hypertension in pregnancy. Hypertension Research, 2013, 36, 834-835.	2.7	14
30	Lower On-treatment Low-Density Lipoprotein Cholesterol and Major Adverse Cardiovascular Events in Women and Men: Pooled Analysis of 10 ODYSSEY Phase 3 Alirocumab Trials. Journal of the American Heart Association, 2018, 7, e009221.	3.7	14
31	The HELLP syndrome (hemolysis, elevated liver enzymes and low platelets): Clinical characteristics and maternal-fetal outcome in 172 patients. Pregnancy Hypertension, 2011, 1, 164-169.	1.4	13
32	Abnormal levels of antioxidant defenses in a large sample of patients with hypertensive disorders of pregnancy. Hypertension Research, 2012, 35, 274-278.	2.7	12
33	The evolving role of CETP inhibition: beyond HDL cholesterol. Lancet, The, 2015, 386, 412-414.	13.7	11
34	LDL-cholesterol lowering and clinical outcomes in hypercholesterolemic subjects with and without a familial hypercholesterolemia phenotype: Analysis from the secondary prevention 4S trial. Atherosclerosis, 2021, 320, 1-9.	0.8	11
35	Familial hypercholesterolemia. Current Opinion in Lipidology, 2020, 31, 111-118.	2.7	11
36	Differences in the prevalence of metabolic syndrome and levels of C-reactive protein after puerperium in women with hypertensive disorders during pregnancy. Hypertension Research, 2010, 33, 1012-1017.	2.7	10

#	ARTICLE	IF	CITATIONS
37	Triglyceride concentrations and non-high-density lipoprotein cholesterol goal attainment in the ODYSSEY phase 3 trials with alirocumab. <i>European Journal of Preventive Cardiology</i> , 2020, 27, 1663-1674.	1.8	9
38	Novel Biomarkers in Heart Failure Beyond Natriuretic Peptides – The Case for Soluble ST2. <i>European Cardiology Review</i> , 2015, 10, 37.	2.2	8
39	Cerebrovascular Disease and Statins. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 778740.	2.4	8
40	Cholesterol Efflux Capacity as a Novel Biomarker for Incident Cardiovascular Events. <i>Circulation Research</i> , 2015, 116, 1646-1648.	4.5	6
41	Promoting high-density lipoprotein function via intravenous infusion: the rebirth of apoA-I Milano?. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2016, 2, 30-31.	3.0	6
42	Implications of ACC/AHA Versus ESC/EAS LDL-C Recommendations for Residual Risk Reduction in ASCVD: A Simulation Study From ADA VINCI. <i>Cardiovascular Drugs and Therapy</i> , 2023, 37, 941-953.	2.6	6
43	Prevalence of familial hypercholesterolemia phenotype and ten-year risk of cardiovascular events in a working population in primary prevention: The ICARIA study. <i>Atherosclerosis</i> , 2021, 338, 39-45.	0.8	2
44	The Postprandial State and its Influence on the Development of Atherosclerosis. <i>Immunology, Endocrine and Metabolic Agents in Medicinal Chemistry</i> , 2011, 11, 1-9.	0.5	1
45	LOWER ON-TREATMENT LOW-DENSITY LIPOPROTEIN CHOLESTEROL IS ASSOCIATED WITH LOWER CARDIOVASCULAR RISK IN VERY HIGH RISK PATIENTS WITH ATHEROSCLEROTIC CARDIOVASCULAR DISEASE: ANALYSES FROM THE ODYSSEY TRIALS. <i>Journal of the American College of Cardiology</i> , 2017, 69, 55. Response by Vallejo-Vaz et al to Letters Regarding Article, “Low-Density Lipoprotein Cholesterol Lowering for the Primary Prevention of Cardiovascular Disease Among Men With Primary Elevations of Low-Density Lipoprotein Cholesterol Levels of 190 mg/dL or Above: Analyses From the WOSCOPS (West of Scotland Coronary Prevention Study) 5-Year Randomized Trial and 20-Year Observational Follow-Up”. <i>Circulation</i> , 2018, 137, 2419-2420.	2.8	1
46	Response by Vallejo-Vaz et al to Letters Regarding Article, “Low-Density Lipoprotein Cholesterol Lowering for the Primary Prevention of Cardiovascular Disease Among Men With Primary Elevations of Low-Density Lipoprotein Cholesterol Levels of 190 mg/dL or Above: Analyses From the WOSCOPS (West of Scotland Coronary Prevention Study) 5-Year Randomized Trial and 20-Year Observational Follow-Up”. <i>Circulation</i> , 2018, 137, 2419-2420.	1.6	1
47	Coexistence of two causes of secondary hypertension in a single patient. <i>Revista Clinica Espanola</i> , 2013, 213, e81-e83.	0.6	0
48	Predictive factors for alirocumab dose increase in patients with heterozygous familial hypercholesterolaemia. <i>Atherosclerosis</i> , 2017, 263, e243.	0.8	0
49	Premature Morbidity And Mortality Among Diagnosed And Potentially Undiagnosed Familial Hypercholesterolemia Patients In The General Population: An Observational Study Of Over 1.7 Million Health Records. <i>Atherosclerosis</i> , 2019, 287, e15.	0.8	0
50	Guest Editorial: Reducing Risk in Familial Hypercholesterolaemia and Severe Dyslipidaemia: Novel Drugs Targeting PCSK9. <i>European Cardiology Review</i> , 2018, 13, 7.	2.2	0